In the third session from the Platelet Reactivity Testing Round Table, the panel discuss treatment options for high-risk PCI patients.
Among the many fascinating points discussed in this session are a number of key issues including:
||Evidence regarding antiplatelet drug response
||Treatment options for antiplatelet therapy in the cathlab
||Interpreting the finding of ARCTIC study
||Bleeding risk in patients with complex disease
||Is there a role for platelet function testing in assessing compliance?
||Value of platelet function testing for assessing whether there is a drug response
||Is the P2'i'12 assay robust enough to titrate a response?
Robert Storey, Professor and Honorary Consultant in Cardiology, Department of Cardiovascular Science, University of Sheffield, UK (Chair)
Jean-Philippe Collet, Groupe Hospitalier Pitié-Salpêtrière, Paris, France
Antonio Colombo, San Raffaele Hospital, Milan, Italy
Jeff Daheln, Chief Scientific Officer, Accumetrics, US
Designed to support the continuous education of practicing physicians, this roundtable shares leading opinion and addresses the following questions and key educational objectives:
- Increase physician awareness of the multidisciplinary role of antiplatelet therapy
- Increase understanding of the role of platelet function testing in high-risk PCI
- Explain the emerging role of PFT in PAD
- Assess the role of antiplatelets in neuro-endovascular procedures
This round table discussion is intended for an international audience, specifically interventional cardiologists, interventional radiologists and aligned healthcare professional involved with antiplatelet therapy.
The Round Table Event was supported by Accumetrics.